HilleVax, Inc. (NASDAQ:HLVX) Short Interest Down 5.6% in March

HilleVax, Inc. (NASDAQ:HLVX) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 448,200 shares, a decrease of 5.6% from the March 15th total of 474,900 shares. Based on an average daily volume of 124,700 shares, the short-interest ratio is currently 3.6 days. Approximately 2.9% of the company’s shares are short sold.

Insider Transactions at HilleVax

In other HilleVax news, major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of HilleVax stock in a transaction that occurred on Thursday, April 4th. The shares were bought at an average price of $14.50 per share, for a total transaction of $128,325.00. Following the acquisition, the insider now directly owns 8,544,187 shares in the company, valued at $123,890,711.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Robert Hershberg sold 11,597 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $173,143.21. Following the completion of the sale, the insider now directly owns 953,831 shares of the company’s stock, valued at approximately $14,240,696.83. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Life Sciences X. L.P. Frazier bought 8,850 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were bought at an average cost of $14.50 per share, for a total transaction of $128,325.00. Following the purchase, the insider now directly owns 8,544,187 shares in the company, valued at approximately $123,890,711.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 78,039 shares of company stock worth $986,464,242. Company insiders own 29.30% of the company’s stock.

Institutional Trading of HilleVax

A number of hedge funds have recently made changes to their positions in HLVX. Russell Investments Group Ltd. purchased a new position in HilleVax during the first quarter valued at $26,000. Federated Hermes Inc. raised its position in shares of HilleVax by 80.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares during the last quarter. UBS Group AG boosted its stake in HilleVax by 9,300.0% in the 4th quarter. UBS Group AG now owns 1,692 shares of the company’s stock worth $28,000 after purchasing an additional 1,674 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in HilleVax by 80.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company’s stock valued at $30,000 after purchasing an additional 781 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in HilleVax by 57.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock valued at $43,000 after purchasing an additional 943 shares during the last quarter. 86.42% of the stock is owned by institutional investors.

HilleVax Stock Performance

Shares of HilleVax stock opened at $12.53 on Thursday. HilleVax has a 12 month low of $9.94 and a 12 month high of $20.22. The firm has a market capitalization of $622.99 million, a P/E ratio of -4.12 and a beta of 0.65. The company has a current ratio of 10.62, a quick ratio of 10.62 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $16.15 and a two-hundred day simple moving average of $14.63.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.02. On average, equities analysts forecast that HilleVax will post -3.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of HilleVax in a research report on Thursday, March 21st.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.